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Abstract 
Streptococcus pyogenes (group A streptococcus, GAS) secretes streptokinase, a potent plasminogen 
activating protein. Among GAS isolates, streptokinase gene sequences (ska) are polymorphic and can be 
grouped into two distinct sequence clusters (termed cluster type-1 and cluster type-2) with cluster type-2 
being further divided into sub-clusters type-2a and type-2b. In this study, far-UV circular dichroism 
spectroscopy indicated that purified streptokinase variants of each type displayed similar secondary 
structure. Type-2b streptokinase variants could not generate an active site in Glu-plasminogen through 
non-proteolytic mechanisms while all other variants had this capability. Furthermore, when compared with 
other streptokinase variants, type-2b variants displayed a 29- to 35-fold reduction in affinity for Glu-
plasminogen. All SK variants could activate Glu-plasminogen when an activator complex was preformed 
with plasmin; however, type-2b and type-1 complexes were inhibited by α2-antiplasmin. Exchanging 
skatype-2a in the M1T1 GAS strain 5448 with skatype-2b caused a reduction in virulence while 
exchanging skatype-2a with skatype-1 into 5448 produced an increase in virulence when using a mouse 
model of invasive disease. These findings suggest that streptokinase variants produced by GAS isolates 
utilize distinct plasminogen activation pathways, which directly affects the pathogenesis of this 
organism. 
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Summary 26 
Streptococcus pyogenes (group A streptococcus, GAS) secretes streptokinase, a potent 27 
plasminogen activating protein. Among GAS isolates, streptokinase gene sequences (ska) are 28 
polymorphic and can be grouped into two distinct sequence clusters (termed cluster type-1 29 
and cluster type-2) with cluster type-2 being further divided into sub-clusters type-2a and 30 
type-2b. In this study, far-UV circular dichroism spectroscopy indicated that purified 31 
streptokinase variants of each type displayed similar secondary structure. Type-2b 32 
streptokinase variants could not generate an active site in Glu-plasminogen through non-33 
proteolytic mechanisms while all other variants had this capability. Furthermore, when 34 
compared to other streptokinase variants, type-2b variants displayed a 29-35 fold reduction in 35 
affinity for Glu-plasminogen. All SK variants could activate Glu-plasminogen when an 36 
activator complex was preformed with plasmin; however type-2b and type-1 complexes were 37 
inhibited by α2-antiplasmin. Exchanging skatype-2a in the M1T1 GAS strain 5448 with 38 
skatype-2b caused a reduction in virulence while exchanging skatype-2a with skatype-1 into 5448 39 
produced an increase in virulence when using a mouse model of invasive disease. These 40 
findings suggest that streptokinase variants produced by GAS isolates utilise distinct 41 
plasminogen activation pathways which directly affects the pathogenesis of this organism. 42 
 43 
Introduction 44 
 45 
Group A streptococcus (GAS; Streptococcus pyogenes) is a human specific pathogen 46 
responsible for a diverse range of diseases which have a major impact on global morbidity 47 
and mortality rates (Carapetis et al., 2005). GAS readily colonize skin and pharyngeal tissue 48 
producing mild superficial infections such as pyoderma, impetigo and pharyngitis. However, 49 
GAS may also produce life-threatening systemic (streptococcal toxic shock syndrome) and 50 
invasive infections (necrotizing fasciitis). Additionally, post-infection sequelae can occur, 51 
which include post streptococcal glomerulonephritis and acute rheumatic fever (Cunningham, 52 
2000).  53 
To cause this diverse range of diseases, GAS employ a broad range of virulence factors that 54 
facilitate bacterial colonization, evasion of the immune response and systemic  55 
dissemination (Tart et al., 2007, Musser & Shelburne, 2009, Olsen et al., 2010, Cole et al., 56 
2011). Virulence factor expression is exquisitely controlled by 13 two-component regulatory 57 
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systems and 30 transcriptional regulators allowing GAS to adapt to the dynamic 58 
physiological conditions encountered during the infection process (Kreikemeyer et al., 2003, 59 
Sumby et al., 2006). Many of the virulence factors produced by GAS interact specifically 60 
with human plasma proteins including fibrinogen, plasmin(ogen), IgG, α2-macroglobulin, 61 
albumin and numerous complement factors (Cunningham, 2000, Walker et al., 2005). GAS 62 
can encounter plasma proteins during invasive systemic dissemination through the 63 
vasculature, but may also be exposed to plasma constituents at the site of infection through 64 
vascular leakage produced during the inflammatory response induced in the host (Herwald et 65 
al., 2004).  66 
The interaction of GAS with the plasminogen activation system of the host is a virulence 67 
mechanism critical for the invasive pathogenesis of this organism (Sun et al., 2004, Khil et 68 
al., 2003, Walker et al., 2005, Sun et al., 2012). Plasminogen (Plg), a single-chain 69 
glycoprotein zymogen of the serine protease plasmin, is a key component of the fibrinolytic 70 
system and is found in plasma and extracellular fluids. GAS can bind plasmin(ogen) to the 71 
cell surface via numerous cell wall associated proteins such as M proteins (PAM, Prp), 72 
glyceraldehyde-3-phosphate (GAPDH) and streptococcal enolase (SEN) (Lahteenmaki et al., 73 
2001, Walker et al., 2005, Cole et al., 2011). GAS also secrete a Plg activating protein, 74 
designated streptokinase (SK), which facilitates the production of both soluble and cell-bound 75 
plasmin activity. The generation of plasmin activity at the site of infection may result in the 76 
activation of host matrix metalloproteinases, degradation of extracellular matrix and/or tissue 77 
barriers and degradation of fibrin networks produced by the host to confine the initial 78 
infection (Walker et al., 2005). These processes allow bacteria to spread to other, normally 79 
sterile, sites of the body. 80 
Unlike mammalian Plg activators that activate Plg by limited proteolytic cleavage, SK binds 81 
to Plg inducing conformational changes in the molecule that results in the formation of an 82 
active site and the production of an enzymatically active complex, termed SK-Plg* (known as 83 
the ‘Conformational Activation Pathway’ or ‘Pathway I’). The conformationally activated 84 
SK-Plg* complex can then sequester substrate molecules of Plg and proteolytically convert 85 
those to plasmin (Boxrud et al., 2000, Boxrud et al., 2004). Plasmin (which has a higher 86 
affinity for SK than Plg) rapidly displaces Plg in the SK-Plg* complex to produce an 87 
irreversibly activated SK-plasmin complex that is the main catalyst responsible for the full 88 
conversion of Plg to plasmin. (known as ‘Direct Proteolytic Activation Pathway’ or ‘Pathway 89 
II’) (Boxrud et al., 2000, Boxrud et al., 2004). These SK-plasmin activator complexes are 90 
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also resistant to inhibition by host plasma inhibitors (α2-antiplasmin (α2-AP) and  91 
α2-macroglobulin), thereby allowing complexes to sequester and activate substrate Plg while 92 
bypassing host protease regulation mechanisms (Parry et al., 2000).  93 
SK is a single chain, 414 amino acid protein, composed of three distinct domains; α (aa 1-94 
150), β (aa 151-287) and γ (aa 288-414) (Wang et al., 1998). The three domains of SK are 95 
separated by two coiled-coil regions while the N- and C- termini of the protein have 96 
disordered flexible structures (Wang et al., 1998). Despite extensive research, the exact role 97 
each domain plays in the activation of human Glu-plasminogen (Glu-Plg) is still not 98 
completely understood. While the majority of structural and functional studies conducted to 99 
date have used the therapeutic form of SK (originally isolated from the group C streptococcal 100 
isolate H46A) (Christensen, 1945), SK proteins from group A streptococcal isolates display 101 
considerable variability and have not been well characterized (Kalia & Bessen, 2004, 102 
McArthur et al., 2008, Kapur et al., 1995). Phylogenetic studies of the most divergent ska 103 
sequences have revealed two main sequence clusters (cluster type-1 and 2) with evidence of 104 
smaller sub-clusters observed in cluster type-2 sequences (cluster type-2a and 2b) (Kalia & 105 
Bessen, 2004, McArthur et al., 2008). While some phenotypic differences displayed by GAS 106 
type-1 and type-2 SK variants have been identified (McArthur et al., 2008), further research 107 
is required to determine if these variants play differing roles in pathogenesis. In this study, we 108 
found that SK variants produced by GAS isolates display different mechanisms of Plg 109 
activation and that this process directly affects GAS pathogenesis. 110 
 111 
Results 112 
 113 
Expression and secondary structural analysis of recombinant SK proteins 114 
To characterize the phenotypic differences displayed by SK proteins from different group A 115 
streptococcal isolates, a cluster type-1 SK protein (SKNZ131), two cluster type-2a SK proteins 116 
(SK5448 and SKNS696) and two cluster type-2b SK proteins (SKALAB49 and SKNS88.2) were 117 
cloned, sequenced and expressed as recombinant proteins. SK from the group C streptococcal 118 
isolate H46A (SKH46A) was also produced as a recombinant protein using the same 119 
methodology for use as a positive control. From the alignment of the deduced amino acid 120 
sequences (Fig. 1), the type-1 SK protein had the most divergent β domain sequence (66% 121 
identity). The β domains from type-2b SK proteins and type-2a SK were more conserved 122 
displaying 85% and 91% identity respectively. The type-1 SK protein also had the most 123 
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conserved α and γ domains (94% and 97% identity) while these domains in type-2a and type-124 
2b proteins were less conserved with identities ranging from 83% to 87% for α domains and 125 
88% to 90% for γ domains. 126 
 127 
Recombinant SK proteins were analyzed for size and purity by SDS-PAGE (Fig. 2A). 128 
Proteins ranged in size from 44 to 49 kDa, which is similar to the sizes observed for native 129 
streptokinase proteins present in GAS culture supernatants (McArthur et al., 2008). All 130 
protein preparations were free from contaminating proteins. Far-UV circular dichroism 131 
spectroscopy was utilized to compare the secondary structure of all recombinant SK proteins. 132 
Despite significant differences in amino acid composition, variant SK proteins had similar 133 
molar residue ellipticity spectra across the full range of wavelengths measured. The output 134 
spectra observed was typical of that expected for an amalgamation of α helical (minima at ~ 135 
210 nm maxima at ~190 nm) and anti-parallel β sheet (minima at ~215 nm and maxima at 136 
~195 nm) spectra indicative of the known structure of SK (Wang et al., 1998) (Fig. 2B). 137 
 138 
Non-proteolytic active site generation in Glu-Plg by variant SK 139 
Active site generation in Glu-Plg by SK variants (SK-Plg*) was examined using the 140 
fluorescent active site titrant 4-methylumbelliferyl p-guanidinobenzoate (MUGB). This 141 
allowed generation of SK-Plg* (conformational activation, Pathway I) to be measured 142 
directly. SKNZ131 (Type 1) displayed the fastest rate of conformational activation of Glu-Plg, 143 
followed by SKH46A (Group C) (Fig. 3A). SKNS696 and SK5448 (type-2a variants) both 144 
displayed very slow rates of Glu-Plg activation while SKALAB49 and SKNS88.2 (type-2b 145 
variants) failed to induce an active site in Glu-Plg (Fig. 3A). As SK mediated Glu-Plg 146 
activation is known to be affected by the conformation of Plg, experiments were conducted in 147 
the absence of Cl- ions to compare the effect of ‘open’ Plg conformation on non-proteolytic 148 
active site generation (McCance & Castellino, 1995). Under these conditions SKNZ131 and 149 
SKH46A displayed increased rates of active site generation that were very similar (Fig. 3B). 150 
The rate of active site generation by type-2a variants (SKNS696 and SK5448) was also 151 
significantly enhanced, but was less than that observed for SKNZ131 and SKH46A (Fig. 3B). 152 
Interestingly, type-2b variants (SKALAB49 and SKNS88.2) both failed to generate an active site in 153 
open Glu-Plg (Fig. 3B). Taken together, these data indicate that type-2b SK variants cannot 154 
conformationally induce an active site in open or closed forms of Glu-Plg.  155 
 156 
Binding affinity of SK variants to human Glu-Plg and plasmin 157 
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To determine if SK variants display differences in affinity for human Glu-Plg and plasmin, 158 
the binding of each SK variant to immobilized Plg and plasmin was assessed using surface 159 
plasmon resonance (SPR) analysis (Fig. S1-2). Group C SK (SKH46A), type-1 SK (SKNZ131) 160 
and type-2a SK (SK5448 and SKNS696) variants all displayed high affinity for human Glu-Plg 161 
(KD ranging from 62 – 88 nM). In contrast, type-2b SK variants had lower affinities for 162 
human Glu-Plg with SKALAB49 and SKNS88.2 displaying a 29 and 35-fold reduction 163 
respectively (Table 1). All SK variants had increased (69 - 347 fold) affinity for plasmin over 164 
Glu-Plg. Group C SK (SKH46A), type-1 SK (SKNZ131) and type-2a SK (SK5448 and SKNS696) 165 
had KD ranging from 0.37 – 1.03 nM, while type-2b (SKALAB49 and SKNS88.2) displayed 166 
slightly lower affinities for plasmin with KD values of 11.5 nM and 6.2 nM respectively 167 
(Table 1). 168 
 169 
Plasminogen activation by variant SK-plasmin activator complexes 170 
The ability of variant SK-plasmin complexes to sequester and activate substrate Plg was 171 
determined by mixing preformed, stoichiometric SK-plasmin activator complexes (5 nM) 172 
with an excess of substrate Glu-Plg and monitoring the generation of plasmin activity using 173 
the chromogenic substrate, S2251. All variant SK-plasmin complexes examined in this study 174 
were capable of efficient substrate Plg activation (Fig 4A).  The plasmin activity displayed by 175 
the plasmin-SK activator complex is known to be resistant to the major physiological plasmin 176 
inhibitor α2-AP (Cederholm-Williams, 1979). In this study, we observed that complexes of 177 
plasmin with SKH46A or type-2a SK (SK5448 and SKNS696) variants were also resistant to 178 
inhibition by α2-AP (Fig. 4B). Interestingly, complexes of plasmin with type-2b SK variants 179 
(SKALAB49 and SKNS88.2) or type-1 SK (SKNZ131) were susceptible to inhibition by α2-AP, 180 
displaying IC50 values of 20 nM, 35 nM and 7 nM respectively (Fig. 4B). 181 
 182 
Role of SK variation in GAS pathogenesis 183 
In vitro characterization of the isogenic mutants 5448Δska, 5448::skaALAB49 and 184 
5448::skaNZ131 indicated all strains maintained similar growth rates and expressed similar 185 
amounts of hyaluronic capsule (Fig. S3A-B). Additionally, 5448Δska did not produce SK 186 
while 5448::skaALAB49 and 5448::skaNZ131 both secreted the exchanged variant of SK (Fig. 187 
S3C). Utilizing the humanized Plg transgenic mouse line AlbPLG1, the virulence of the wild-188 
type 5448 and the isogenic mutant GAS strains, 5448Δska, 5448::skaALAB49 and 189 
5448::skaNZ131 was assessed. The virulence of GAS strain 5448 has been well characterized 190 
and has previously been shown to be virulent in this mouse model (Fig. 5) (Maamary et al., 191 
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2010, Walker et al., 2007). In comparison to the wild-type 5448 strain, the virulence of 192 
5448Δska and 5448::skaALAB49 was significantly reduced (P < 0.05; 50% vs. 10% mortality) 193 
(Fig. 5). Conversely, the virulence of 5448::skaNZ131, is increased when compared to the wild-194 
type 5448 strain, although these data were not statistically significant (P > 0.05; 100% vs. 195 
50% mortality) (Fig. 5). Taken together, these data suggest that the unique Plg activation 196 
kinetics/properties displayed by the different SK variants affect the pathogenesis of GAS. 197 
 198 
Discussion 199 
GAS is a versatile human pathogen capable of causing a wide range of human diseases. The 200 
broad pathogenicity of GAS is underpinned by the genetic diversity displayed by clinical 201 
isolates of the species. There is a large amount of evidence in the literature describing how 202 
the absence or presence of virulence genes or changes in the complex regulatory mechanisms 203 
controlling the expression of these genes can alter the pathogenicity of a particular GAS 204 
isolate (Sumby et al., 2006, Walker et al., 2007, Kreikemeyer et al., 2003, Musser & 205 
Shelburne, 2009, Cole et al., 2011). Similarly, allelic variation of specific virulence genes 206 
may also influence the pathogenicity of GAS isolates however, these changes may be more 207 
subtle and therefore more difficult to characterize. 208 
Allelic variation of the ska gene has been well characterized (Kalia & Bessen, 2004, Kapur et 209 
al., 1995, McArthur et al., 2008). Bioinformatical analyses of predicted SK protein sequences 210 
suggested that SK variants maintain similar secondary structure despite differences in the 211 
amino acid sequences (Kapur et al., 1995). In this study, the six SK proteins were specifically 212 
chosen as representatives of divergent sequence clusters and despite significant amino acid 213 
sequence differences, all recombinant SK proteins displayed similar secondary structures as 214 
indicated by individual CD spectra. This data further supports the hypothesis that selection 215 
pressure may be placing structural constraints on SK molecules (Kapur et al., 1995). 216 
However, biochemical analysis of the SK variants presented in this study clearly 217 
demonstrates that these variants do display a number of different phenotypic properties, 218 
which alter the ability of these molecules to interact with and activate human Glu-Plg. 219 
GAS SK variants display significant differences in ability to non-proteolytically generate an 220 
active site in Glu-Plg. Type-2b SK variants could not induce the formation of an active site in 221 
Glu-Plg. Additionally, type-2b SK variants have a 25 fold less affinity for Glu-Plg when 222 
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compared to other SK variants which all displayed similar high affinities (Table 1).  223 
Therefore, the inability of type-2b SK variants to produce an active site in Glu-Plg may be 224 
the result of the type-2b variants failing to interact with Glu-Plg. However, type-1 SK, group-225 
C SK and type-2a SK molecules which all bind to Glu-Plg with similar, high affinity, also 226 
displayed different rates of active site formation in Glu-Plg. These data suggest that while the 227 
formation of the nascent SK-Plg complex plays a role in the generation of a conformationally 228 
re-arranged active site in Glu-Plg, other protein specific changes may also be affecting this 229 
process. 230 
SKH46A mutants with deletions or site directed amino acid changes within the α domain, also 231 
form complexes with Glu-Plg that display delays in the generation of amidolytic activity (Fay 232 
& Bokka, 1998, Wang et al., 1999, Rodríguez et al., 1995, Young et al., 1995). In particular, 233 
residues 1-59 of the SK α domain have been shown to be critical for SK mediated Plg 234 
activation (Young et al., 1995, Reed et al., 1999, Mundada et al., 2003) SK mutants (such as 235 
α domain truncation mutants and numerous amino terminal site directed mutants) also display 236 
reduced amidolytic activity, reduced Plg affinity and increased susceptibility to α2-AP 237 
inhibition (Fay & Bokka, 1998, Sazonova et al., 2004, Rodríguez et al., 1995, Boxrud et al., 238 
2000, Mundada et al., 2003). Upon mixing of SK and Glu-Plg, SK is rapidly cleaved at the 239 
Lys59-Ser60 peptide bond once bound to Plg (Shi et al., 1994). The N-terminal peptide 240 
remains associated (non-covalently) with the SK-Plg complex and is required for non-241 
proteolytic active site induction and stabilization of the activator complex (Parrado et al., 242 
1996, Young et al., 1995, Wang et al., 1999, Mundada et al., 2003). For SK to induce an 243 
active site in Plg, the SK Ile1 residue must be positioned within the Plg molecule so that it can 244 
form a salt bridge with Asp740 of Plg (Wang et al., 1999). SK mutants lacking this residue 245 
cannot induce an active site in Plg through non-proteolytic mechanisms (Wang et al., 1999, 246 
Mundada et al., 2003). While all SK variants examined in this study had an N-terminal Ile 247 
residue, cluster type-2 SK proteins contain over 11 amino acid changes in the 1-59 region 248 
(Fig. 1). These changes may prevent the correct positioning of the N-terminal fragment 249 
within the SK-Plg complex thereby preventing (or slowing) non-proteolytic active site 250 
formation in Glu-Plg.  251 
The physiological inhibitor of plasmin, α2-AP, is a member of the serpin family and tightly 252 
regulates the activity of plasmin in plasma (Aoki et al., 1993). When plasmin reacts with  253 
α2-AP, the serpin is cleaved resulting in a covalently bound complex of plasmin and α2-AP 254 
that is inactive (Shieh & Travis, 1987). Activator complexes consisting of Plg/plasmin and 255 
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therapeutic SK (SKH46A) are known to be resistant to α2-AP inhibition (Cederholm-Williams, 256 
1979). Similarly, we found complexes of plasmin and type-2a SK (SK5448 and SKNS696) 257 
variants were also resistant to inhibition by α2-AP, while complexes of plasmin and  258 
type-2b SK variants (SKALAB49 and SKNS88.2) or type-1 SK (SKNZ131) were not (Fig. 4B). The 259 
susceptibility of type-2b SK for inhibition by α2-AP and inability of this variant to non-260 
proteolytically generate in active site in Glu-Plg suggests that GAS isolates expressing a 261 
type-2b SK molecule have evolved novel mechanisms to control SK mediated Plg activation. 262 
The apparent requirement of plasmin for type-2b SK mediated activation of Plg also suggests 263 
that Plg activation may be restricted to areas where there is free plasmin (i.e. at the sites of 264 
fibrinolysis). Alternatively, SK variants may require additional cofactors (either host or 265 
bacterial in origin) to facilitate successful Plg activation, such as: fibrinogen, SEN, GAPDH 266 
or PAM (McArthur et al., 2008, Gaffney et al., 1988, Lahteenmaki et al., 2001).  267 
Subversion of the host Plg activation system is a well documented pathogenic mechanism 268 
used by GAS and other bacterial pathogens to cause disease (Boyle & Lottenberg, 1997, 269 
Coleman & Benach, 1999, Cole et al., 2011). SK mediated Plg activation has been shown to 270 
play a critical role in the invasive pathogenesis of GAS (Sun et al., 2004, Cole et al., 2011). 271 
M1T1 GAS strains are considered a highly virulent clone capable of causing serve invasive 272 
disease of humans. Consequently, the M1T1 GAS strain 5448 used in this study (which 273 
contains a type-2a ska allele) is highly virulent for the human Plg transgenic mouse strain that 274 
was used in these experiments (Cole et al., 2011, Maamary et al., 2010, Walker et al., 2007). 275 
In this study, the acquisition of the type-1 ska allele increased M1T1 virulence. Similarly, 276 
GAS strain NZ131 (type-1 SK) has previously been shown to be virulent in other mouse 277 
models of GAS infection. (Kuo et al., 1998, Tsao et al., 2001, Li et al., 2011). When the 278 
type-2a ska allele of the M1T1 strain 5448 is replaced with a type-2b allele (skaALAB49), the 279 
invasive pathogenesis of this strain is reduced, similar to a level seen for the isogenic ska 280 
deletion mutant (5448Δska) (Fig. 5). Previous studies conducted in our laboratory have 281 
shown that wild-type ALAB49 is avirulent in this mouse model (Maamary et al., 2010). This 282 
result indicates that type-2b SK cannot reproduce the in vivo function of a type-2a SK in a 283 
M1T1 genetic background and suggests the requirement of plasmin by type-2b SK to form an 284 
efficient activator complex affects the invasive pathogenesis of GAS. Previous studies have 285 
shown a strong association between cluster type-2b alleles and skin tropic emm pattern D 286 
strains containing the high affinity Plg binding M-protein PAM (Kalia & Bessen, 2004). 287 
Taken together, these observations suggest that type-2b SK proteins require bacterial co-288 
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factors present only in a subset of strains for efficient plasmin acquisition or that 289 
reduced/restricted Plg activation kinetics produced by type-2b SK in vivo may be beneficial 290 
for successful long term skin infections such as impetigo. Similarly, the Plg activator 291 
staphylokinase from the ubiquitous skin colonizer, Staphylococcus aureus, also requires 292 
plasmin for efficient Plg activation, which suggests this mechanism of Plg activation may be 293 
advantageous for skin colonization (Grella & Castellino, 1997). Additionally, Plg acquisition 294 
and activation mechanisms have been documented for commensal strains of oral streptococci, 295 
which also suggests this process may also be involved in maintaining long term infections 296 
(Kinnby et al., 2008).  297 
This study confirms the importance of SK mediated Plg activation in GAS pathogenesis and 298 
highlights a mechanism whereby variability in this important virulence factor can influence 299 
the pathogenesis of this organism. Characterizing GAS SK variants represents a novel 300 
approach to elucidate the mechanism of SK-mediated Plg activation. Therefore, future 301 
comparative studies that characterize GAS SK variants in more detail will help to identify 302 
critical residues involved in SK function and could assist the rational design of new drugs 303 
targeting this specific interaction which may be useful in treating GAS infections. 304 
 305 
Experimental Procedures 306 
 307 
Bacterial strains and reagents used in this study 308 
GAS isolates NZ131 (Simon & Ferretti, 1991), ALAB49 (Svensson et al., 2000), NS88.2 309 
(McKay et al., 2004), NS696 (McKay et al., 2004), 5448 (Aziz et al., 2004) and  310 
S. equisimilis strain H46A (Christensen, 1945) were used in this study. All streptococci 311 
strains were routinely cultured at 37°C on horse-blood agar (Biomerieux, Sydney, NSW, 312 
Australia) or in static liquid cultures of Todd-Hewitt broth (BD, Sydney, NSW, Australia) 313 
supplemented with 1% (w/v) yeast extract (Oxoid, Adelaide, SA, Australia) (THY medium). 314 
Escherichia coli strains JM109 and M15[pREP4], were used as hosts for plasmid 315 
construction and protein expression respectively and were cultured at 37°C in Luria-Bertani 316 
broth. Where appropriate, antibiotics were used for selection at the following concentrations: 317 
chloramphenicol, 2 μg mL-1 for streptococci and 100 μg mL-1 for E. coli; erythromycin, 2 μg 318 
mL-1 for streptococci and 200 μg mL-1 for E. coli; kanamycin, 50 μg mL-1; and ampicillin, 319 
100 μg mL-1 for E. coli.  Glu-Plg and α2-AP were purchased from Haematologic 320 
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Technologies, Essex Junction, VT, USA. Chromogenic substrate H-D-Val-Leu-Lys-321 
pNA·2HCl (S-2251) was from Chromogenix, Mölndal, Sweden. 322 
 323 
Cloning, expression and purification of recombinant SK proteins 324 
The SK encoding gene (ska) from each GAS strain was amplified from genomic DNA by 325 
polymerase chain reaction (PCR). PCR primers were designed to incorporate BamH1 and 326 
PstI restriction sites at the 5’ and 3’ ends of the fragment respectively. This allowed cloning 327 
into pQE-30 (Qiagen, Valencia, CA, USA) for expression of recombinant SK as a poly-328 
histidine tagged fusion protein. A Factor Xa recognition site was incorporated at the 5’ end of 329 
sense primers to facilitate removal of the poly-histidine tag after purification and expose the 330 
functional Ile1 N-terminal residue of SK. The following primers were used: Type-1, type-2a 331 
and type-2b ska sense (5’-GTGGATCCATCGAGGGAAGGATTGCTGGGTATGAATGG 332 
CTG-3’). H46A ska sense (5’-GTGGATCCATCGAGGGAAGGATTGCTGGACCTGAG 333 
TGGCTG-3’). Type-1, type-2a and type-2b (NS88.2) ska antisense (5’-TGCTGCAGTTA 334 
TTTGTCTTTAGGGTTATC-3’). H46A and type-2b (ALAB49) ska antisense (5’-TGCTG 335 
CAGTTATTTGTCGTTAGGGTTATC-3’) (Sigma-Aldrich, Sydney, NSW, Australia). The 336 
cloned PCR products were sequenced in entirety and no sequence errors were detected. 337 
Recombinant SK protein expression in transformed M15[pREP4] was induced by addition of 338 
1 mM isopropyl-1-thio-b-D-galactopyranoside to log-phase cells. Three hours later, cells 339 
were harvested by centrifugation, lysed using an EmulsiFlex-C5 (Avestin Inc., Ottawa, ON, 340 
Canada) and purified under native conditions using nickel-nitriloacetic acid affinity 341 
chromatography. Native recombinant SK proteins were cleaved from the poly-histidine tag 342 
by incubation with Factor Xa (Sigma-Aldrich, Sydney, NSW, Australia) for 12-36 h at 4°C. 343 
Post Factor Xa treatment a secondary truncation product was observed for all SK 344 
preparations during sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 345 
analysis. Nanoelectrospray-ionization mass spectrometry was undertaken to determine the 346 
lower molecular weight product was the result of non-specific proteolysis occurring at Arg401 347 
in the C-terminus of recombinant SK molecules (data not shown). To separate full-length 348 
recombinant SK from truncation products, a secondary purification step using anion 349 
exchange chromatography was undertaken. This resulted in the retrieval of full-length 350 
recombinant SK, free of contaminating proteins. 351 
 352 
 353 
 354 
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Far-UV circular dichroism (CD) spectroscopy 355 
CD spectroscopy was performed using a J-810 spectropolarimeter (Jasco, Tokyo, Japan) at 356 
room temperature. Samples were prepared in 10 mM phosphate buffer (pH 7.4) to a final 357 
concentration of 100-300 µg mL-1. Spectra representing the average of six scans were 358 
collected from 190 nm to 250 nm at 1 nm intervals, with a path length of 1 mm. Molar 359 
residue ellipticity (Ө) was calculated using the following formula: [Ө] = Ө x 100 x molecular 360 
weight (kDa)/concentration (mg mL-1) x path length x number of amino acids. 361 
 362 
Non-proteolytic active site generation in Glu-Plg  363 
Non-proteolytic active site generation in Glu-Plg by SK variants was examined using the 364 
fluorescent active site titrant 4-methylumbelliferyl p-guanidinobenzoate (MUGB) (Marker 365 
Gene Technologies, Inc., Eugene, OR, USA) in a POLARstar Omega fluorescence 366 
spectrophotometer (BMG LABTECH, Ortenberg, HE, GER). Glu-Plg (200 nM) was added to 367 
a black 96-well micro-plate containing MUGB (1 µM) in assay buffer (50 mM Tris-HCl, 100 368 
mM NaCl, pH 7.4) at 37 °C. To initiate the reaction, SK was added to a final concentration of 369 
400 nM in a total volume of 100 µL and the development of fluorescence was monitored 370 
continuously with excitation at 355 nm and emission at 460 nm. Data was normalised by 371 
subtracting a control reaction of 200 nM Glu-Plg and 1 µM MUGB. This accounted for 372 
intrinsic fluorescence associated with buffer and protein species, as well as non-specific 373 
hydrolysis of MUGB over the course of reactions.  374 
 375 
Surface plasmon resonance  376 
Binding of SK variants to Glu-Plg and plasmin were examined via Biacore T200 (Biacore 377 
AB, Uppsala, Sweden) at 25ºC. Ligand Glu-Plg and plasmin were immobilized on a Series S 378 
Sensor Chip CM4 (Biacore AB, Uppsala, Sweden) via primary amino acids using an amine 379 
coupling kit according to the manufacturer's instructions (Biacore AB, Uppsala, Sweden). 380 
Briefly, the chip was activated with a 1:1 mixture of 0.2 M N-ethyl-N'-(3-381 
dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccimide. Glu-Plg and plasmin 382 
were coated onto the chip at 40 µg mL-1 in 10 mM sodium acetate (pH 4) to a level of ~1500 383 
and ~250 response units respectively. Unoccupied binding sites were blocked using 1 M 384 
ethanolamine, pH 8.5. A blank immobilized CM4 cell was used as a reference. Analytes were 385 
diluted into running buffer (10 mM HEPES, 150 mM NaCl, 0.005% P-20, pH 7.4) and 386 
kinetic assays were performed by injecting recombinant SK proteins at varying 387 
concentrations (0-1600 nM), for 200-300 s at a flow rate of 20 μL min-1 with a 600 s 388 
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dissociation period. Regeneration of the ligand surface was achieved with 6 M urea in 389 
running buffer for 15 s at 20 μL min-1. Glu-Plg interaction biosensorgram data were prepared 390 
for analysis using Scrubber2 (BioLogic Software, Campbell, ACT, Australia) and data was 391 
analyzed manually using a two-component heterogeneous surface model with data curves fit 392 
using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). For Glu-Plg interactions 393 
with each SK variant, one binding component accounting for ~30-90% of the total response 394 
showed relatively fast association rate constants (ka values) and dissociation rate constants (kd 395 
values), with ka showing a linear dependence on [SK], while the other showed slow on and 396 
off rates independent of [SK]; we chose to ignore this second non-specific component and 397 
determined equilibrium binding constants (KD) from the ratio of kd and ka for the specific 398 
binding component. For plasmin interactions, ka, kd and KD were calculated from sensorgrams 399 
by non-linear fitting of the association and dissociation curves according to a 1:1 Langmuir 400 
binding model using the Biacore T200 evaluation software supplied by the manufacturer 401 
(Biacore AB, Uppsala, Sweden). 402 
 403 
Glu-Plg activation assays 404 
The Plg activation potential of SK variants were studied by the addition of stoichiometric SK-405 
plasmin activator complexes (final concentration 5 nM) that had been preformed for 5 min at 406 
37°C, to assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing 407 
Glu-Plg (500 nM) and S-2251 (500 µM) in a total volume of 100 µL. The exponential 408 
generation of plasmin was monitored by change in absorbance at 405 nm and measured for 409 
30 min using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA, 410 
USA) at 37°C. 411 
 412 
Inhibition of amidolysis by α2-antiplasmin 413 
Stoichiometric complexes of SK-plasmin were formed by mixing SK (400 nM) and plasmin 414 
(200 nM) for 5min at 37°C. Complexes were diluted to 20 nM in assay buffer in the presence 415 
of increasing α2-AP concentration (0-400 nM) and incubated at 37°C for 15 min. The 416 
reactions were initiated by the addition of S-2251 (final concentration 500 µM) and change in 417 
absorbance at 405 nm was measured at 37°C. IC50 values were determined by plotting 418 
percentage of residual activity (Vmax) versus log α2-AP concentration and fit to a sigmoidal 419 
dose response curve using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) 420 
 421 
 422 
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Allelic exchange mutagenesis 423 
Isogenic mutants of GAS strain 5448 were produced by replacing the parental ska5448 with 424 
either skaALAB49, skaNZ131 or with the chloramphenicol acetyltransferase (cat) gene via precise, 425 
allelic replacement using a modified protocol to Buchanan et al. (2006). To construct 426 
plasmids for allelic exchange, skaALAB49 and skaNZ131 were amplified from genomic DNA by 427 
PCR using sense primer: (5’-TTCTTCCTGTCTGTTTATGTACCCGCAGCTACTTGA 428 
TACC-3’) and antisense primer: (5’-TTGTCCTCTTCTGTTTTGGCTACCAAGAACGCTT 429 
GATTG-3’) (Sigma-Aldrich, Sydney, NSW, Australia), to include GAS chromosomal 430 
flanking regions 834 bp upstream and 853 bp downstream of ska, in addition to regions 431 
homologous to the temperature sensitive, erythromycin resistant shuttle vector pHY304-LIC. 432 
For knockout plasmid construct p5448∆ska, upstream (369 bp) and downstream (538 bp) ska 433 
DNA fragments containing regions homologous to pHY304-LIC and cat were amplified 434 
using sense primer (5’- TTCTTCCTGTCTGTTTAGATGAGGGCCTACTTGCATC-3’) and 435 
antisense (5’-GTGGCTTTTTTCTCCATACGGTCTGGTAGCCATCCAT-3’) for the 436 
upstream homology region and sense primer (5’-GTGGCTGGGCGGGGCGTAAAA 437 
GCTTACAGCTACCTGCGT-3’) and antisense (5’-TTGTCCTCTTCTGTTTCGGAC 438 
CAATGGCTAAGAAAG-3’) for the downstream homology region. The cat gene was 439 
amplified using the sense primer (5’-GGAGAAAAAAGCCACTGGATATACCACC-3’) and 440 
antisense primer (5’-ACGCCCCGCCCAGCCACTCATCGCAATACTGTT-3’). Single-441 
strand overhangs were created on all PCR products and PmeI pHY304-LIC shuttle vector by 442 
T4 DNA polymerase treatment at 22°C for 30 min.  Treated pHY304-LIC was combined 443 
with equal concentrations of ska upstream/downstream regions and the cat gene to create the 444 
Δska knock-out construct, or with either skaALAB49 or skaNZ131 gene fragments to create allelic 445 
exchange constructs. Complementary sequences were allowed to anneal on ice for 30 min 446 
before transformation into chemically competent E. coli. The purified plasmid constructs 447 
were confirmed by DNA sequencing analysis and transformed into GAS strain 5448. 448 
Erythromycin resistant transformants were grown at the permissive temperature for plasmid 449 
replication (30°C). Single-crossover chromosomal insertions were selected by shifting to the 450 
non-permissive temperature (37°C) while maintaining erythromycin selection. Single cross-451 
over mutants were incubated overnight at 30°C to allow for looping out of the inserted 452 
plasmid and then patched onto both THY agar and THY agar containing erythromycin and 453 
incubated at 37°C. This allowed selection of double crossover mutants encoding in-frame 454 
allelic exchanges and was confirmed using DNA sequence analysis. The allelic exchange 455 
mutant strains were designated 5448::skaALAB49, 5448::skaNZ131 and 5448Δska.  456 
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Transgenic murine infection model  457 
Humanized Plg transgenic AlbPLG1 mice, heterozygous for the human Plg gene (Sun et al., 458 
2004), were used as the animal model for determining GAS invasive potential as previously 459 
described (Walker et al., 2007). Briefly, GAS isolates were grown in THY medium at 37°C 460 
to logarithmic phase (OD600 = 0.6), washed with sterile 0.7% (w/v) NaCl and appropriately 461 
diluted to prepare the inoculum. Cohorts of 9-10 mice were infected with a 100 µL 462 
intradermal injection containing 5448 (Maamary et al., 2010) (3.9 x 107 CFU/dose), 463 
5448::Δska (3.7 x 107 CFU/dose), 5448::skaALAB49 (4.6 x 107 CFU/dose), or 5448::skaNZ131 464 
(3.7 x 107 CFU/dose) and mortality was recorded over a 10-day period. 465 
 466 
Statistical analyses 467 
Differences in survival of humanized plasminogen transgenic mice infected with GAS strains 468 
5448, 5448::Δska, 5448::skaALAB49, or 5448::skaNZ131 were determined by the log-rank test. 469 
Differences were considered statistically significant at P < 0.05. All statistical tests were 470 
performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). 471 
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Table 1. Association (kon) and dissociation (koff) rate constants and apparent equilibrium dissociation (KD) constants for the interaction of SK 635 
variants with immobilized Plg and plasmin by SPR. 636 
Analyte   Ligand Plg Ligand Pm 
 ka (M-1 s-1) kd (s-1) KD (nM) ka (M-1 s-1) kd (s-1) KD (nM) 
SKH46A 2.9 ± 0.5 x 104 1.8 ± 0.3 x 10-3 62 ± 19 8.6 ± 0.2 x 105 3.1 ± 0.5 x 10-4 0.37 ± 0.04 
SKNZ131 2.8 ± 0.7 x 103 2.5 ± 0.6 x 10-4 88 ± 12 1.1 ± 0.8 x 106 1.1 ± 0.4 x 10-3 0.76 ± 0.09 
SK5448 1.1 ± 0.2 x 106 72.6 ± 1.4 x 10-3 66 ± 7 1.0 ± 0.6 x 106 8.3 ± 0.7 x 10-4 0.96 ± 0.39 
SKNS696 1.2 ± 0.2 x 106 84.1 ± 3.4 x 10-3 70 ± 17 1.2 ± 0.8 x 106 9.4 ± 0.1 x 10-4 1.03 ± 0.47 
SKALAB49 4.6 ± 0.4 x 104 81.3 ± 0.8 x 10-3 1767 ± 199 4.2 ± 0.4 x 105 4.3 ± 0.3 x 10-3 11.55 ± 3.03 
SKNS88.2 7.9 ± 0.5 x 104 170.0 ± 3.0 x10-3 2153 ± 512 4.4 ± 0.3 x 105 2.2 ± 0.6 x 10-3 6.22 ± 2.70 
 637 
Glu- Plg binding data was prepared for analysis using Srubber2 (BioLogic Software, Campbell, ACT, Australia) and analyzed by fitting data to a 638 
heterogeneous ligand population model using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) as described under ‘Experimental 639 
Procedures’. Values represent the mean ± SD. Plasmin binding data were calculated by non-linear fitting of the association and dissociation 640 
curves according to a 1:1 Langmuir binding model using the Biacore T200 evaluation software (Biacore AB, Uppsala, Sweden)641 
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Figure Legends 642 
 643 
Fig. 1. ClustalW Multiple alignment of deduced amino acid sequences of the SK protein 644 
variants used in this study. Amino acid residues identical to those in SKH46A are indicated 645 
with a dot while amino acid changes have been indicated. Non-conserved amino acid changes 646 
are highlighted in grey. 647 
 648 
Fig. 2. SDS-PAGE and Far-UV circular dichroism spectroscopy analysis of recombinant SK 649 
proteins used in this study. (A) Variant SKH46A (lane 1), SKNZ131 (lane 2), SK5448 (lane 3), 650 
SKNS696 (lane 4), SKALAB49 (lane 5) and SKNS88.2 (lane 6) were separated by 10% SDS-PAGE 651 
under reducing conditions. Molecular weight standards in kDa are indicated. (B) All SK 652 
variants have similar molar residue ellipticity values and CD out-put spectrum structure 653 
across the full range of wavelengths indicating no differences in secondary structure.  654 
 655 
Fig. 3. Non-proteolytic active site generation in Glu-Plg by SK variants and influence of Glu-656 
Plg conformation on SK-Plg* generation. Glu-Plg (200 nM) was added to 1 µM MUGB in 657 
(A) Cl- present assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.4) or (B) chloride Cl- 658 
absent buffer (50 mM Tris pH 7.4) at 37 °C. To initiate the reaction, SK was added to a final 659 
concentration of 400 nM in a total volume of 100 µL and the development of fluorescence 660 
was monitored continuously with excitation at 355 nm and emission at 460 nm.  661 
 662 
Fig. 4. Plg activation by SK-plasmin variant activator complexes and inhibition of variant 663 
SK-plasmin complexes by α2-antiplasmin. (A) SK was preformed with plasmin for 5 min at 664 
37°C (5 nM), then added to assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% Tween-20, 665 
pH 7.4) containing Glu-Plg (500 nM) and S-2251 (500 µM).  The generation of plasminogen 666 
activation activity was monitored at an absorbance of 405 nm. (B) Stoichiometric complexes 667 
of SK-plasmin (20 nM) were preformed for 5 min at 37°C in assay buffer (10 mM HEPES, 668 
150 mM NaCl, 0.01 % Tween-20, pH 7.4) and subsequently incubated for 15 min at 37°C 669 
with α2-antiplasmin (final concentration 0 – 400 nM). The reactions were initiated by 670 
addition of S-2251 (500 µM) to complex mixtures and the percentage of residual activity of 671 
the SK-plasmin complexes was determined by measuring the absorbance at 405 nm.  672 
 673 
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Fig. 5. Survival curves after subcutaneous infection of humanized Plg transgenic AlbPLG1 674 
mice with GAS strain 5448 and isogenic mutants. 5448 (3.9 x 107 CFU/dose; n = 10) 675 
(Maamary et al., 2010), 5448::skaALAB49 (4.6 x 107 CFU/dose; n = 10), 5448Δska (3.7 x 107 676 
CFU/dose; n = 10) or 5448::skaNZ131 (3.7 x 107 CFU/dose; n = 9). 677 
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